Floatz logo

Velpatasvir

Treatment Complication

Alexandria UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Treatment Complication cohort.

Asset / SponsorPhaseRating
AUTOLOGOUS CONDITIONED PLASMA
Star Spine and Sport
Phase 4BB
Sofosbuvir
Alexandria University
Phase 4BB
NEPENTHE
Hopital Lariboisière
Phase 4BB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BB
NADROPARIN
Rijnstate Hospital
Phase 4BB

View all 37 →

Same molecule, other indications

Velpatasvir is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
84 / 100
View asset →
chronic hepatitis C virus infectionDormant
BB
Indicative ·
65 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →